These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20118966)

  • 1. Slaying RAS with a synthetic lethal weapon.
    Bommi-Reddy A; Kaelin WG
    Cell Res; 2010 Feb; 20(2):119-21. PubMed ID: 20118966
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer: disrupted cell-to-cell talk about growth.
    Robinson A
    CMAJ; 1993 Jul; 149(1):53-5. PubMed ID: 8319155
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategies to optimize the use of targeted agents for tumor therapy.
    Becker JC; Ugurel S; Schrama D
    J Dtsch Dermatol Ges; 2008 Apr; 6(4):281-5. PubMed ID: 18205839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Discovery by Targeting Mutant KRAS.
    Ye N
    Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
    [No Abstract]   [Full Text] [Related]  

  • 5. Cellular maturation and oncogene expression during drug-induced differentiation in vitro: a brief review.
    Biedler JL; Spengler BA; Ross RA
    Prog Clin Biol Res; 1990; 354A():287-312. PubMed ID: 2247493
    [No Abstract]   [Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors for suppression of tumorigenic growth of Ras-transformed cells: PAK-ing in the signals.
    Gallick GE
    Cancer J; 2000; 6(4):217-9. PubMed ID: 11038141
    [No Abstract]   [Full Text] [Related]  

  • 7. Farnesyl transferase inhibitors.
    Li T; Sparano JA
    Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted therapies: aiming for the bull's-eye.
    Gaguski ME
    ONS Connect; 2007 Jul; 22(7):8-12. PubMed ID: 17694778
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
    J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific repression of mutant K-RAS by 10-23 DNAzyme: sensitizing cancer cell to anti-cancer therapies.
    Yu SH; Wang TH; Au LC
    Biochem Biophys Res Commun; 2009 Jan; 378(2):230-4. PubMed ID: 19014906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversion and rereversion in ras-transformed cells.
    Marshall CJ
    Immunol Ser; 1990; 51():89-106. PubMed ID: 2128917
    [No Abstract]   [Full Text] [Related]  

  • 12. trans-Dominant suppressor mutations of the H-ras oncogene.
    Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
    Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting RAS: The Elusive Prize.
    Bates SE
    Clin Cancer Res; 2015 Apr; 21(8):1796. PubMed ID: 25878359
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumorigenicity of human induced pluripotent stem cells depends on the balance of gene expression between p21 and p53.
    Moriguchi H; Chung RT; Sato C
    Hepatology; 2010 Mar; 51(3):1088-9. PubMed ID: 19957368
    [No Abstract]   [Full Text] [Related]  

  • 15. The interplay between ras oncogenes and tumor suppressor genes in experimental carcinogenesis.
    Balmain A; Brown K; Bremner R
    Immunol Ser; 1990; 51():75-88. PubMed ID: 2128916
    [No Abstract]   [Full Text] [Related]  

  • 16. The insulin receptor substrate-1: a biomarker for cancer?
    Baserga R
    Exp Cell Res; 2009 Mar; 315(5):727-32. PubMed ID: 18851963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Kinase inhibitors for the therapy of malignant melanoma].
    Becker JC; Schrama D; Bröcker EB; Houben R
    J Dtsch Dermatol Ges; 2005 Oct; 3(10):762-7. PubMed ID: 16194153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells.
    Adler V; Bowne W; Kamran I; Michl J; Friedman FK; Chin E; Zenilman M; Pincus MR
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):491-8. PubMed ID: 18066549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis and secondary expression profiling of candidate genes deregulated in conjunction with oncogenic Ras signaling.
    Raudies O; Kuban RJ; Hamacher F; Klein-Hitpass L; Tchernitsa OI; Sers C; Herzel HP; Schäfer R
    Adv Enzyme Regul; 2005; 45():63-84. PubMed ID: 16023704
    [No Abstract]   [Full Text] [Related]  

  • 20. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R; Kloog Y
    Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.